Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

References

• ByrdJCStilgenbauerSFlinnIW2004Chronic lymphocytic leukemiaHematology American Society of Hematology Education Program BookWashington, DCAmerican Society of Hematology16383
   Google Scholar
• CatovskyDRichardsSMatutesE2007Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trialLancet370230917658394
   PubMed Web of Science ®Google Scholar
• ChesonBDBennetJMGreverM1996National Cancer Institute – sponsored Working Group Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentBlood87499078652811
   PubMed Web of Science ®Google Scholar
• CortelezziAPasquiniMCSarinaB2005A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemiaHaematologica904101215749678
   PubMed Web of Science ®Google Scholar
• DelannoyAHaniqueGFerrantA19932-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabineN Engl J Med3288128094888
   PubMed Web of Science ®Google Scholar
• DohnerHFischerKBentzM1995p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemiasBlood85158097888675
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRHopfingerG2006Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemiaBlood1078859116219797
   PubMed Web of Science ®Google Scholar
• ElterTBorchmannPSchulzH2005Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialJ Clin Oncol2370243116145065
   PubMed Web of Science ®Google Scholar
• FaderlSThomasDAO’BrienS2003Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood10134131512522009
   PubMed Web of Science ®Google Scholar
• FaderlSFerrajoliAWierdaWG2006The combination of Alemtuzumab [Continuous Intravenous Infusion (civ) followed by subcutaneous injection (sc)] plus Rituximab has activity in patients (pts) with relapsed chronic lymphocytic leukemia (CLL) [abstract]Blood108282716809617
   PubMed Web of Science ®Google Scholar
• FerrajoliAO’BrienSMCortesJE2003Phase II study of alemtuzumab in chronic lymphoproliferative disordersCancer98773812910522
   PubMed Web of Science ®Google Scholar
• FlinnIWNeubergDSGreverMR2007Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997J Clin Oncol25793817283364
   PubMed Web of Science ®Google Scholar
• GhobrialIMOttemanLAWhiteWL2003An EBV-positive lymphoproliferative disorder after therapy with alemtuzumabN Engl J Med3492570214695424
   PubMed Web of Science ®Google Scholar
• GilleeceMHDexterTM1993Effect of Campath-1H antibody on human hematopoietic progenitors in vitroBlood828078127687895
   PubMed Web of Science ®Google Scholar
• GreenwoodJClarkMWaldmannH1993Structural motifs involved in human IgG antibody effector functionsEur J Immunol2310981048477804
   PubMed Web of Science ®Google Scholar
• GreverMRLeibyJMKrautEH1985Low-dose deoxycoformycin in lymphoid malignancyJ Clin Oncol311962012993534
   PubMed Web of Science ®Google Scholar
• HaleGRebelloPBrettmanLR2004Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationBlood1049485515090452
   PubMed Web of Science ®Google Scholar
• HeitWBunjesDWiesnethM1986Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogenic bone marrow transplantationBr J Haematol64479863539172
   PubMed Web of Science ®Google Scholar
• JohnsonSSmithAGLofflerH1996Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLLLancet347143288676625
   PubMed Web of Science ®Google Scholar
• JuliussonGElmhorn-RosenborgALiliemarkJ1992Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabineN Engl J Med3271056611355853
   PubMed Web of Science ®Google Scholar
• KeatingMJKantarjianHTalpazM1989Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood7419252473795
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSKantarjianH1993Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agentBlood812878848499626
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSKontoyannisD2002aResults of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemiaLeuk Lymphoma4317556212685828
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainV2002bTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood9935546111986207
   PubMed Web of Science ®Google Scholar
• KeatingMJCoutreSRaiK2004Management guidelines for use of Alemtuzumab in B-cell chronic lymphocytic leukemiaClin Lymphoma4220715072613
   PubMedGoogle Scholar
• KennedyBRawstronACarterC2002Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemiaBlood992245711877305
   PubMed Web of Science ®Google Scholar
• KippsTJBeutlerELichtmanMACollerBSKippsTJSeligsohnU2001Chronic lymphocytic leukemia and related diseasesWilliams HematologyMcGraw-HillNew York, USA11631194
   Google Scholar
• KnospeWHLoebVJrHuguleyCMJr1974Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemiaCancer33555624812772
   PubMed Web of Science ®Google Scholar
• LenihanDJAlencarAJYangD2004Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndromeBlood104655815073032
   PubMed Web of Science ®Google Scholar
• LeporrierMChevretSCazinB2001Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood9823192511588025
   PubMed Web of Science ®Google Scholar
• LozanskiGHeeremaNAFlinnIW2004Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood10332788114726385
   PubMed Web of Science ®Google Scholar
• LundinJKimbyEBjorkholmM2002Phase II trial of subcutaneous alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Blood10076877312130484
   PubMed Web of Science ®Google Scholar
• McCuneSLGockermanJPMooreJO2002Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaLeuk Lymphoma431007101112148879
   PubMed Web of Science ®Google Scholar
• MontserratE2002Current and developing chemotherapy for CLLMed Oncol19S11S1912180487
   PubMed Web of Science ®Google Scholar
• MontilloMTedeschiAMiqueleizS2007Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL) [abstract]Blood1103133
   Web of Science ®Google Scholar
• MoretonPKennedyBLucasG2005Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalJ Clin Oncol232971915738539
   PubMed Web of Science ®Google Scholar
• NabhanCRosenST2002Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemiaSemin Oncol29 Suppl 2758011842392
   PubMed Web of Science ®Google Scholar
• NabhanCPattonDGordonLI2004A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)Leuk Lymphoma4522697315512816
   PubMed Web of Science ®Google Scholar
• NguyenDDCaoTMDuganK2002Cytomegalovirus viremia during CAMPATH-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemiaClin Lymphoma310511012435283
   PubMedGoogle Scholar
• O’BrienSKantarijanHEsteyE1994Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukaemia refractory to fludarabine therapyN Engl J Med330319227904047
   PubMed Web of Science ®Google Scholar
• O’BrienSKeatingMJMocarskiES2006Updated guidelines on the management of Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with AlemtuzumabClin Lymphoma Myeloma71253017026823
   PubMedGoogle Scholar
• OkenMMKaplanME1979Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemiaCancer Treat Rep634417371799
   PubMedGoogle Scholar
• OsterborgADyerMJBunjesD1997Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic LeukemiaJ Clin Oncol151567749193354
   PubMed Web of Science ®Google Scholar
• OsujiNCDel GiudiceIMatutesE2005The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53Haematologica901435616219582
   PubMed Web of Science ®Google Scholar
• PettittARMatutesEOscierD2006Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defectsLeukemia201441516738694
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFR2000Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med3431750711114313
   PubMed Web of Science ®Google Scholar
• RaiKRFreterCEMercierRJ2002Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabineJ Clin Oncol203891712228210
   PubMed Web of Science ®Google Scholar
• RossmannEDLundinJLenkeiR2001Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodiesHematol J2300611920265
   PubMedGoogle Scholar
• RowanWTiteJTopleyP1998Cross-linking of the Campath-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cellsImmunology95427369824507
   PubMed Web of Science ®Google Scholar
• SayalaHAMoretonPJonesRA2006Final report of the UKCLL02 Trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group) [abstract]Blood10834
   Web of Science ®Google Scholar
• SavenAPiroLD19932-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignanciesLeuk Lymphoma10Suppl4398097654
   PubMedGoogle Scholar
• StilgenbauerSDohnerH2002Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapyN Engl J Med347452312167696
   PubMed Web of Science ®Google Scholar
• StilgenbauerSWinklerDKroberA2004Subcutaneous Campath-1H (alemtuzumab) in fludarabine refractory refractory CLL; interim analysis of the CLL2H Study of the German CLL Study Group (GCLLSG) [abstract]Blood10447815044252
   PubMed Web of Science ®Google Scholar
• WendtnerCMRitgenMSchweighoferCD2004Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia in first remission- experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)Leukemia18109310115071604
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSFaderlS2006Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract]Blood10831
   Web of Science ®Google Scholar